Advanced in Non-Small Cell Lung Cancer (NSCLC)

Dr. Alina Basnet

Hematology | Oncology
Guthrie Medical Group PC
34 W Main St, 
Cortland, NY 
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Guthrie Medical Group PC
34 W Main St, 
Cortland, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alina Basnet is a Hematologist and an Oncologist in Cortland, New York. Dr. Basnet is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Urothelial Cancer, Bone Marrow Aspiration, and Nephrectomy. Dr. Basnet is currently accepting new patients.

Her clinical research consists of co-authoring 71 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 8 articles in the study of Non-Small Cell Lung Cancer (NSCLC).

Specialties
Hematology
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
Guthrie Cortland Regional Medical Center
Conemaugh Memorial Medical Center
University Hospital S U N Y Health Science Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

GUTHRIE MEDICAL GROUP PC
34 W Main St, Cortland, NY 13045

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Procedure, Other
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Procedure, Drug, Biological, Other
Study Drugs: Gemcitabine, Cisplatin, Pegfilgrastim
Study Phase: Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: a Randomized Phase 3 Non-Inferiority Trial (IMAGINE)
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: a Randomized Phase 3 Non-Inferiority Trial (IMAGINE)
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Avelumab
Study Phase: Phase 3
View 3 Less Clinical Trials

65 Total Publications

Use of a Simulated Tumor Board to Teach Oncology and Multidisciplinary Collaboration to Pre-clinical Medical Students.
Use of a Simulated Tumor Board to Teach Oncology and Multidisciplinary Collaboration to Pre-clinical Medical Students.
Journal: Journal of cancer education : the official journal of the American Association for Cancer Education
Published: May 13, 2025
Similar Doctors
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Stephen L. Graziano
Hematology Oncology | Hematology | Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Stephen L. Graziano
Hematology Oncology | Hematology | Oncology

Department Of Medicine Medical Serv Grp At Suny Hlth Sci Ctr Syr In

750 E Adams St, 
Syracuse, NY 
 (32.5 miles away)
315-464-4457
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Graziano is a Hematologist Oncology specialist and a Hematologist in Syracuse, New York. Dr. Graziano is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), Bone Marrow Aspiration, and Endoscopy.

Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Ajeet Gajra
Hematology | Oncology
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Ajeet Gajra
Hematology | Oncology

Hematology-Oncology Associates Of Cny, PC

5008 Brittonfield Pkwy, 
East Syracuse, NY 
 (37.3 miles away)
315-472-7504
Languages Spoken:
English
See accepted insurances

Ajeet Gajra is a Hematologist and an Oncologist in East Syracuse, New York. Dr. Gajra is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and Breast Cancer.

Serge Dauphin
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Serge Dauphin
Hematology Oncology | Hematology | Oncology
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Serge Dauphin
Hematology Oncology | Hematology | Oncology

Arnot Ogden Medical Center

600 Roe Ave, 
Elmira, NY 
 (45.8 miles away)
607-737-4100
Languages Spoken:
English
See accepted insurances

Serge Dauphin is a Hematologist Oncology specialist and a Hematologist in Elmira, New York. Dr. Dauphin is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Familial Colorectal Cancer, Anal Cancer, Lung Adenocarcinoma, Thrombocytopenia, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Basnet's expertise for a condition
ConditionClose
    View All 29 Advanced Conditions
    View All 53 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile